Hangzhou Jiuyuan Gene Engineering Co .,Ltd

What Hangzhou Jiuyuan Gene Engineering Co .,Ltd does

Hangzhou Jiuyuan Gene Engineering Co., Ltd. (杭州九源基因生物医药股份有限公司, HKEX: 2566.HK) is a Hangzhou, China-based biopharmaceutical and medical device company founded in December 1993 that develops, manufactures, and commercializes recombinant protein and peptide drugs and a rhBMP-2 bone repair material across four therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. The company operates six proprietary technology platforms covering recombinant proteins, peptides, monoclonal antibody biosimilars, drug-device combinations, long-acting pegylated formulations, and subcutaneous drug delivery, with flagship product Guyoudao (骨优导) ranked number one in China's bone repair materials market at 21.8% share in 2023 and being China's first approved rhBMP-2 bone repair material.

The product portfolio includes the originator rhG-CSF Jilifen (吉粒芬), which broke US-Japan market monopoly in 1996; LMWH/anticoagulants Jipailin and Yinuojia; the IL-11 thrombocytopenia treatment Jijufen; oncology supportive care products Jifuwei (fulvestrant) and Jitansu (fosaprepitant); the long-acting pegylated leukocyte promoter Jixin Fen; a liraglutide NDA secured in 2023; and semaglutide biosimilars Jiyou Tai (for type 2 diabetes) and Jike Qin (for weight management), with Jiyou Tai being the first semaglutide biosimilar production application filed in China in April 2024. Pipeline assets include the next-generation JY23 bone repair material and the JY43 daratumumab biosimilar (China's second approved clinical trial), with recombinant human hyaluronidase (rHuPH20) registered as a pharmaceutical excipient.

The company earns revenue primarily through one-time product sales via its Pharmacy Services Company subsidiary running direct hospital sales to orthopedic, oncology, and metabolic disease departments across China, plus international distribution through exclusive channel partners (Fosun Pharma for MENA, Sub-Saharan Africa, and select ASEAN; a Brazil exclusive distributor; and a first shipment to Indonesia in April 2026). 2025 sales exceeded CNY 1.3 billion with over 1,800 employees, and the company listed on the Hong Kong Stock Exchange on November 28, 2024 to fund pipeline and international expansion.

Name

Hangzhou Jiuyuan Gene Engineering Co .,Ltd

Legal name

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (杭州九源基因生物医药股份有限公司)

Website

https://china-gene.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Hangzhou Jiuyuan Gene Engineering (HKEX: 2566.HK) is a Hangzhou-based biopharmaceutical company developing recombinant protein, peptide, and antibody drugs plus the rhBMP-2 bone repair material Guyoudao across orthopedics, metabolic, oncology, and hematology therapeutic areas for Chinese hospitals and international partners.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (3391)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAIAFAA

Monoclonal Antibody (mAb) Biosimilars

Healthcare & Life Sciences/Pharmaceuticals/Biosimilars

SECONDARYHLAAAIAI

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAIAAAJ

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Biopharmaceutical manufacturing
• Recombinant protein drugs
• Bone repair materials
• GLP-1 receptor agonists
• Gene engineering pharmaceuticals

Headquarters

HQ city

Hangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical product sales: The company generates revenue primarily through the sale of biopharmaceutical products including rhG-CSF (吉粒芬), low molecular weight heparin (吉派林), interleukin-11 (吉巨芬), enoxaparin (亿喏佳), and GLP-1 drugs. Products are distributed through hospital and pharmacy channels across China.
2. Medical device sales: Revenue from Guyoudao (骨优导), the company's innovative drug-device combination bone repair material, sold to hospitals and orthopedic centers in China and international markets.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

Hangzhou Jiuyuan Gene Engineering researches, develops, manufactures, and commercializes biopharmaceutical products and medical devices. Its portfolio spans recombinant protein drugs (rhG-CSF, interleukin-11), anticoagulants (LMWH, enoxaparin), oncology supportive care products (fulvestrant, fosaprepitant), GLP-1 receptor agonist biosimilars (liraglutide, semaglutide), and an innovative drug-device combination bone repair material (rhBMP-2).

Product overview

Hangzhou Jiuyuan Gene Engineering Co., Ltd is a biopharmaceutical company that has developed a diversified portfolio of biological drugs and medical devices. The product portfolio includes: (1) Pharmaceutical products spanning bone marrow support (JILIFEN rhG-CSF, JIXINFEN PEG-hG-CSF, JIJUFEN IL-11), anticoagulation (JIPAILIN LMWH, YINUOJIA Enoxaparin), oncology (JIFUWEI Fulvestrant), and antiemetics (JITANSU Fosaprepitant); (2) A flagship medical device - Guyoudao (骨优导), China's first approved rhBMP-2 bone repair material that dominates the domestic market at 21.8% share; (3) A growing GLP-1 pipeline including semaglutide biosimilar (Jiyou Tai/Jike Qin) and liraglutide for metabolic diseases; (4) Antibody biosimilars including JY43 (daratumumab); and (5) Enabling technology products like recombinant human hyaluronidase (rHuPH20). The company operates across four therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology.

Differentiator

Problem solved

Functional benefit

Brands

• JILIFEN (吉粒芬): Filgrastim (rhG-CSF) - Leukocyte promotion medicine for treating neutropenia
• GUYOUDAO (骨优导)
• JIPAILIN (吉派林)
• JIJUFEN (吉巨芬)
• JIFUWEI (吉芙惟)
• JITANSU (吉坦苏)
• JIXINFEN (吉新芬)
• JILIXIN (吉立欣)
• YINUOJIA (亿喏佳)
• JIOUTING (吉欧停)
• Ji You Tai (吉优泰)
• Ji Ke Qin (吉可亲)

Products and services

• JILIFEN (吉粒芬 / Filgrastim / rhG-CSF) Recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection for leukocyte promotion in patients with neutropenia, including chemotherapy-induced neutropenia. Sold to hospitals and oncology centers.
• JIPAILIN (吉派林 / Low Molecular Weight Heparin Sodium) Low molecular weight heparin (LMWH) sodium injection, an anticoagulant therapy used to prevent and treat thromboembolic disorders. Sold to hospitals and pharmacy channels.
• JIJUFEN (吉巨芬 / Human Interleukin-11) Human interleukin-11 for injection, used for thrombocytopenia treatment and bone marrow support, primarily in oncology supportive care.
• YINUOJIA (亿喏佳 / Enoxaparin Sodium) Enoxaparin sodium injection, a low molecular weight heparin anticoagulant for the prevention and treatment of deep vein thrombosis and related conditions.
• GUYOUDAO (骨优导 / rhBMP-2 Bone Repair Material) China's first approved and commercially launched rhBMP-2-containing bone repair material, an innovative drug-device combination used for bone healing, spinal fusion, fracture healing, and bone nonunion treatment in orthopedic surgery. Ranked #1 in China's bone repair material market with 21.8% share in 2023.
• JIFUWEI (吉芙惟 / Fulvestrant Injection) Fulvestrant injection, a hormonal therapy for breast cancer (estrogen receptor antagonist) sold to oncology centers and hospitals.
• Liraglutide (利拉鲁肽) GLP-1 receptor agonist peptide injection for type 2 diabetes glycemic control, sold to endocrinology departments and pharmacy channels.
• JITANSU (吉坦苏 / Fosaprepitant Dimeglumine) Fosaprepitant dimeglumine for injection, an NK1 receptor antagonist antiemetic used to prevent chemotherapy-induced nausea and vomiting. Sold to oncology centers.
• JIXINFEN (吉新芬 / Pegylated rhG-CSF / PEG-hG-CSF) Pegylated long-acting form of rhG-CSF for leukocyte promotion in cancer patients receiving chemotherapy; reduces dosing frequency to one injection per chemotherapy cycle.
• Recombinant Human Hyaluronidase (rHuPH20) Recombinant human hyaluronidase (rHuPH20) pharmaceutical excipient produced via gene engineering in CHO cells; used for subcutaneous drug delivery, assisted reproduction, ophthalmology, and medical aesthetics.
• JIYOU TAI (吉优泰 / Semaglutide Biosimilar for Type 2 Diabetes, JY29-2) Semaglutide biosimilar injection (GLP-1 receptor agonist) for glycemic control in adult type 2 diabetes patients; positioned to be China's first approved commercialized semaglutide biosimilar.
• JIKE QIN (吉可亲 / Semaglutide Biosimilar for Weight Management) Semaglutide biosimilar injection (GLP-1 receptor agonist) targeting obesity/weight management indication, expanding the semaglutide franchise beyond type 2 diabetes.
• JIOUTING (吉欧停) Pharmaceutical product for intravenous use offered as part of the company's marketed pharmaceutical portfolio.
• JILIXIN (吉立欣) Pharmaceutical injectable product offered as part of the company's marketed pharmaceutical portfolio.

Quantifiable outcome

• Guyoudao achieved 21.8% market share ranking #1 in China's bone repair materials market by sales revenue in 2023
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (复星医药)coreChannel Partner/ Reseller/ Distributor · 28 May 2025Fosun Pharma granted exclusive overseas commercialization rights for multiple Jiuyuan Gene products including semaglutide, Guyoudao, and JY-23. The exclusive rights cover clinical development, registration, manufacturing and commercialization in MENA (Middle East and North Africa), Sub-Saharan Africa, and select ASEAN countries. This is a strategic partnership enabling Jiuyuan's international expansion leveraging Fosun's established distribution network in these regions.
• Suzhou Novoprotein Technology Co., Ltd. (苏州近岸蛋白质科技股份有限公司)minorChannel Partner/ Reseller/ Distributor · 11 February 2025Jiuyuan Gene authorized 近岸蛋白 to be the exclusive distributor for recombinant human hyaluronidase (rHuPH20) in Greater China. Jiuyuan's rHuPH20 product is already registered with CDE (F20240000443) and is produced via gene engineering in CHO cells. 近岸蛋白 leverages its customer base in the recombinant protein field to promote commercial applications of rHuPH20.
• Brazilian partner (Brazil exclusive agent)minorChannel Partner/ Reseller/ Distributor · 1 December 2023Brazilian partner granted exclusive distribution rights for Guyoudao in Brazil. The partnership passed ANVISA (Brazilian health regulatory agency) certification with zero defects in December 2023, enabling market entry in Brazil.

Scale indicators9 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Yantai Zhenghai Bio-tech: Chinese biomedical company focused on bone repair materials including dental membranes, biological patches, and bone regeneration products. Most directly comparable to Jiuyuan's Guyoudao bone repair franchise in China, competing in the same domestic orthopedic regeneration market.
• Shanghai Henlius Biotech: Leading Chinese biosimilar developer focused on mAb biosimilars including rituximab, trastuzumab, and bevacizumab. Most directly comparable to Jiuyuan in biosimilar strategy, Chinese market focus, and recombinant protein/mAb technology platforms, though Henlius is much larger and listed on HKEX with global ambitions.
• Innovent Biologics: Major Chinese biotech developing both innovative biologics and biosimilars including GLP-1 candidate mazdutide. Comparable to Jiuyuan in biosimilar-plus-innovative strategy, HKEX listing, oncology and metabolic disease focus, and partnership-led commercialization model.
• 3SBio: Chinese biopharmaceutical company specializing in recombinant protein drugs, biosimilars (including G-CSF, EPO, and mAbs), and innovative biologics. Highly comparable to Jiuyuan in recombinant protein manufacturing, biosimilar pipeline, and direct hospital sales model across China.
• Gan & Lee Pharmaceuticals: China's leading insulin and GLP-1 peptide drug manufacturer with biosimilar insulin analogs and liraglutide/semaglutide development. Highly comparable to Jiuyuan's peptide drug platform, metabolic disease focus, and biosimilar pipeline targeting diabetes and obesity markets.
• United Laboratories International Holdings: Hong Kong-listed Chinese pharma with biosimilars (insulin, antibiotics, intermediates) and recombinant protein manufacturing. Comparable to Jiuyuan in biosimilar pipeline, recombinant protein production scale, and API/finished dosage form manufacturing capability.
• Tonghua Dongbao Pharmaceutical: Chinese biopharma specializing in recombinant protein drugs including insulin analogs and biosimilars. Comparable to Jiuyuan in recombinant protein platform technology, biosimilar pipeline, China-focused sales force, and competing in diabetes therapeutic area.

Others

• Shanghai Fosun Pharmaceutical: Major Chinese pharmaceutical group that is Jiuyuan's overseas commercialization partner. Listed here as an ecosystem participant/channel partner rather than direct competitor, providing international market access in MENA, Africa, and ASEAN for Jiuyuan's products.

Broad incumbents

• Hansoh Pharmaceutical Group: Largest Chinese innovative pharma with broad oncology, CNS, and metabolic portfolios. Adjacent comparable as a larger HKEX-listed Chinese biopharma with biosimilar/innovative mix, though Hansoh operates at much larger scale with more diversified therapeutic coverage.

Emerging players

• Sciwind Biosciences: Emerging Chinese biotech focused on metabolic disease therapeutics including novel long-acting GLP-1 agonists. Competes directly with Jiuyuan in the Chinese GLP-1 space, representing a newer entrant with innovative peptide technology targeting diabetes and obesity.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hangzhou Jiuyuan Gene Engineering Co .,Ltd